Anita Vasudevan

Special Counsel
Full contact info

Experience

Cooley advises Inflammatix on $102M Series D Round

March 24, 2021

Cooley advised Inflammatix, a pioneering molecular diagnostics company, on its $102 million Series D funding round to support the development and commercialization of the company’s novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures. Inflammatix’s diagnostics rapidly read the patient’s immune response to infections across multiple mRNA biomarkers using machine learning algorithms. The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. 

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto

Related Practices & Industries

Iconic Therapeutics Series C Financing

January 13, 2016

Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.

Related contacts

Mark Weeks
Partner, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto
Michael Tuscan
Partner, Washington, DC
Marya Postner
Partner, Palo Alto

Related Practices & Industries

IDEV Technologies $310 Million Acquisition by Abbott Labs

July 17, 2013

Palo Alto, Calif. – Cooley represented IDEV Technologies in its $310 million acquisition by Abbott Laboratories. IDEV is a privately-held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. The transaction is expected to close by the end of 2013.

Related contacts

Mark Weeks
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Jacqueline Grise
Partner, Washington, DC
Kevin King
Partner, Washington, DC
Anita Vasudevan
Special Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC

Triphase Accelerator Corporation in its Partnership and Option-to-acquire Arrangement with Celgene

September 2, 2019

Cooley advised Triphase Accelerator Corporation in its partnership and option-to-acquire arrangement with Celgene to advance a pre-clinical therapeutic developed to treat leukemia and other blood cancers. Under the terms of the agreement, Triphase received an upfront payment of $40 million and, upon exercise of the option, will be eligible to receive up to $940 million in contingent development, regulatory and sales milestones.

Related contacts

Marya Postner
Partner, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto
Lauren Creel
Partner, Palo Alto
Allison Pang
Associate, Palo Alto

Related Practices & Industries

BrightFarms Closes $100 Million Series E

November 12, 2020

Cooley advised BrightFarms on its $100 million Series E financing. Partner Mark Medearis led the Cooley team advising BrightFarms, which is a leading next-generation indoor farming company supplying U.S. grocery retailers with packaged salad greens.

Related contacts

Mark Medearis
Senior Counsel, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto
Nikita Appaswami
Associate, Palo Alto
Kris Tamashiro
Paralegal Specialist, Palo Alto
Howard Morse
Partner, Washington, DC
Megan Browdie
Partner, Washington, DC
Julia R. Brinton
Associate, Washington, DC

Related Practices & Industries